Jose Maria Pelayo-Teran
Overview
Explore the profile of Jose Maria Pelayo-Teran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gomez-Revuelta M, Pelayo-Teran J, Juncal-Ruiz M, Vazquez-Bourgon J, Suarez-Pinilla P, Romero-Jimenez R, et al.
Int J Neuropsychopharmacol
. 2020 Jan;
23(4):217-229.
PMID: 31974576
Background: Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of...
12.
Gomez-Revuelta M, Pelayo-Teran J, Juncal-Ruiz M, Ortiz-Garcia de la Foz V, Vazquez-Bourgon J, Gonzalez-Pinto A, et al.
Int J Neuropsychopharmacol
. 2018 Sep;
21(12):1090-1101.
PMID: 30215723
Background: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of...
13.
Pelayo-Teran J, Gajardo-Galan V, Gomez-Revuelta M, Ortiz-Garcia de la Foz V, Ayesa-Arriola R, Tabares-Seisdedos R, et al.
Eur Psychiatry
. 2018 Apr;
52:29-37.
PMID: 29614389
Background: The duration of untreated psychosis (DUP) has been associated with negative outcomes in psychosis; however, few studies have focused on the duration of active psychotic symptoms after commencing treatment...
14.
Pelayo-Teran J, Martinez-Perez M, Zapico-Merayo Y
Rev Psiquiatr Salud Ment
. 2017 Aug;
10(4):219-220.
PMID: 28844296
No abstract available.
15.
Pelayo-Teran J, Gajardo Galan V, de la Ortiz-Garcia de la Foz V, Martinez-Garcia O, Tabares-Seisdedos R, Crespo-Facorro B, et al.
Eur Arch Psychiatry Clin Neurosci
. 2016 Nov;
267(4):315-323.
PMID: 27796500
Relapses may represent a critical hazard in schizophrenia spectrum disorders as they are associated with an increased risk of a clinical and functional deterioration. Preventing relapse after recovering from a...
16.
Crespo-Facorro B, Pelayo-Teran J, Son J
Neurol Ther
. 2016 Aug;
5(2):105-130.
PMID: 27553839
Implementing the most suitable treatment strategies and making appropriate clinical decisions about individuals with a first episode of psychosis (FEP) is a complex and crucial task, with relevant impact in...
17.
Samara M, Leucht C, Leeflang M, Anghelescu I, Chung Y, Crespo-Facorro B, et al.
Am J Psychiatry
. 2015 Jun;
172(7):617-29.
PMID: 26046338
Objective: How long clinicians should wait before considering an antipsychotic ineffective and changing treatment in schizophrenia is an unresolved clinical question. Guidelines differ substantially in this regard. The authors conducted...
18.
Diaz I, Pelayo-Teran J, Perez-Iglesias R, Mata I, Tabares-Seisdedos R, Suarez-Pinilla P, et al.
Psychiatry Res
. 2012 Nov;
206(2-3):181-7.
PMID: 23159063
The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were...
19.
Caseiro O, Perez-Iglesias R, Mata I, Martinez-Garcia O, Pelayo-Teran J, Tabares-Seisdedos R, et al.
J Psychiatr Res
. 2012 Jun;
46(8):1099-105.
PMID: 22721546
Background: Preventing relapse during the first years of illness has a critical impact on lifelong outcomes in schizophrenia. A better understanding and improvement in factors which influence relapse should diminish...
20.
Pelayo-Teran J, Suarez-Pinilla P, Chadi N, Crespo-Facorro B
Curr Pharm Des
. 2012 Jun;
18(32):5024-35.
PMID: 22716151
Cannabis use may be considered as an additional risk factor in a diathesis-stress model of schizophrenia where the risk of developing the illness would be higher in genetic vulnerable people....